Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2000

View Archived Issues

New comparative data reported concerning in vitro activity of daptomycin

Neurocrine Biosciences reports positive results from phase I/II malignant glioma trial

NicOx granted CTX for HCT-1026 phase II trial in UK

Neuprex BLA filing postponed due to insufficient data

Yamanouchi prepares cyanophenyl derivatives for prostate disorders

Protease inhibitors with a hydroxamate structure patented by Cephalon

Novel synthetic antimicrobial agents targeting microbial enzymes emerge from R&D at Cubist

Newly issued U.S. patent protects Questcor's position in anti-HCV drug discovery

Novartis to develop and market Celgene's novel form of Ritalin

SB researchers design potent and selective 5-HT4 receptor antagonist

New ketolide antibiotics in the Pfizer pipeline

Lantus approved by FDA for type I and II diabetes

Compounds and methods of treating proliferative diseases and hypercholesterolemia

Inhibitors of p38 MAP kinase a focus of R&D at Vertex

DM-232: a highly potent piracetam-like nootropic agent from a new class

Vanguard Medica, CeNeS confirm merger negotiations

FDA clears Isotechnika to commence human trials with ISAtx-247

Potent, selective dopamine D3 antagonist with good oral bioavailability & CNS penetration identified

Inflazyme issued U.S. patent for potential asthma compounds

Successful application of antedrug approach to the development of topical antiinflammatory agents

Large-scale production of Endostatin protein under way

AxyS Advanced Technology to merge with Discovery Partners

Orally administered glutathione for preventing the flu

OraPharma's NDA for MPTS accepted for FDA review

Novel approach to stopping metastasis of aggressive prostate tumors

CV Therapeutics identifies next clinical candidate

Lexicon Genetics issued patent on novel protein target for cancer treatments

Results for SUN-N4057 in cat model of cerebral ischemia presented at Japanese stroke meeting